Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant.

Durand CM, Chattergoon MA.

J Clin Invest. 2019 Jun 24;130. pii: 129982. doi: 10.1172/JCI129982. eCollection 2019 Jun 24.

2.

CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans.

El-Diwany R, Soliman M, Sugawara S, Breitwieser F, Skaist A, Coggiano C, Sangal N, Chattergoon M, Bailey JR, Siliciano RF, Blankson JN, Ray SC, Wheelan SJ, Thomas DL, Balagopal A.

Sci Adv. 2018 Aug 1;4(8):eaat0843. doi: 10.1126/sciadv.aat0843. eCollection 2018 Aug.

3.

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.

Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM.

Ann Intern Med. 2018 Apr 17;168(8):533-540. doi: 10.7326/M17-2871. Epub 2018 Mar 6.

4.

HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.

Veenhuis RT, Freeman ZT, Korleski J, Cohen LK, Massaccesi G, Tomasi A, Boesch AW, Ackerman ME, Margolick JB, Blankson JN, Chattergoon MA, Cox AL.

J Clin Invest. 2017 Dec 1;127(12):4352-4364. doi: 10.1172/JCI95375. Epub 2017 Oct 30.

5.

Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection.

Veenhuis RT, Astemborski J, Chattergoon MA, Greenwood P, Jarosinski M, Moore RD, Mehta SH, Cox AL.

Clin Infect Dis. 2017 Mar 1;64(5):589-596. doi: 10.1093/cid/ciw771. Epub 2016 Dec 7.

6.

TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.

Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, Pan F, Pardoll DM, Cox AL.

Cancer Discov. 2016 Dec;6(12):1366-1381. Epub 2016 Sep 28.

7.

HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon.

Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, Blankson JN, Pardoll D, Cox AL.

PLoS Pathog. 2014 May 1;10(5):e1004082. doi: 10.1371/journal.ppat.1004082. eCollection 2014 May.

8.

Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication.

Serti E, Werner JM, Chattergoon M, Cox AL, Lohmann V, Rehermann B.

Gastroenterology. 2014 Jul;147(1):209-220.e3. doi: 10.1053/j.gastro.2014.03.046. Epub 2014 Mar 28.

9.

Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection.

Osburn WO, Levine JS, Chattergoon MA, Thomas DL, Cox AL.

J Viral Hepat. 2013 Jun;20(6):404-13. doi: 10.1111/jvh.12052. Epub 2013 Feb 6.

10.

High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection.

Chattergoon MA, Levine JS, Latanich R, Osburn WO, Thomas DL, Cox AL.

J Infect Dis. 2011 Dec 1;204(11):1730-40. doi: 10.1093/infdis/jir642. Epub 2011 Oct 7.

11.

HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells.

Muthumani K, Shedlock DJ, Choo DK, Fagone P, Kawalekar OU, Goodman J, Bian CB, Ramanathan AA, Atman P, Tebas P, Chattergoon MA, Choo AY, Weiner DB.

J Immunol. 2011 Sep 15;187(6):2932-43. doi: 10.4049/jimmunol.1100594. Epub 2011 Aug 19.

12.

Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo.

Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, Zharikova D, Chattergoon M, Maguire H, Muthumani K, Ugen K, Weiner DB.

Gene Ther. 2010 Jan;17(1):72-82. doi: 10.1038/gt.2009.112. Epub 2009 Oct 22.

PMID:
19847203
13.

DR5 activation of caspase-8 induces DC maturation and immune enhancement in vivo.

Chattergoon MA, Muthumani K, Tamura Y, Ramanathan M, Shames JP, Saulino V, Robinson TM, Montaner LJ, Weiner DB.

Mol Ther. 2008 Feb;16(2):419-26. Epub 2007 Dec 18.

14.

Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway.

Ramanathan MP, Chambers JA, Pankhong P, Chattergoon M, Attatippaholkun W, Dang K, Shah N, Weiner DB.

Virology. 2006 Feb 5;345(1):56-72. Epub 2005 Oct 21.

15.

HIV-1 Viral protein-r (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo.

Muthumani K, Choo AY, Hwang DS, Dayes NS, Chattergoon M, Mayilvahanan S, Thieu KP, Buckley PT, Emmanuel J, Premkumar A, Weiner DB.

Mol Ther. 2005 Nov;12(5):910-21. Epub 2005 Jul 11.

16.

Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.

Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB.

J Immunol. 2005 Jul 1;175(1):112-23.

17.

Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice.

Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB.

Vaccine. 2004 Apr 16;22(13-14):1744-50.

PMID:
15068858
18.

Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86.

Agadjanyan MG, Chattergoon MA, Holterman MJ, Monzavi-Karbassi B, Kim JJ, Dentchev T, Wilson D, Ayyavoo V, Montaner LJ, Kieber-Emmons T, Sekaly RP, Weiner DB.

J Immunol. 2003 Oct 15;171(8):4311-9.

19.

Engineering cross-presentation in vivo.

Chattergoon MA, Shames JP, Weiner DB.

Expert Opin Biol Ther. 2003 Sep;3(6):887-94. Review.

PMID:
12943447
20.

Mechanism of HIV-1 viral protein R-induced apoptosis.

Muthumani K, Choo AY, Hwang DS, Chattergoon MA, Dayes NN, Zhang D, Lee MD, Duvvuri U, Weiner DB.

Biochem Biophys Res Commun. 2003 May 9;304(3):583-92. Review.

PMID:
12729593
21.

Next generation DNA vaccines for HIV-1.

Boyer JD, Chattergoon M, Muthumani K, Kudchodkar S, Kim J, Bagarazzi M, Pavlakis G, Sekaly R, Weiner DB.

J Liposome Res. 2002 Feb-May;12(1-2):137-42. Review.

PMID:
12604047
22.

Prospects for an HIV vaccine: conventional approaches and DNA immunization.

Baumeister MA, Chattergoon MA, Weiner DB.

Biotechnol Genet Eng Rev. 2002;19:205-42. Review. No abstract available.

PMID:
12520879
23.

Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin.

Kragol G, Hoffmann R, Chattergoon MA, Lovas S, Cudic M, Bulet P, Condie BA, Rosengren KJ, Montaner LJ, Otvos L Jr.

Eur J Biochem. 2002 Sep;269(17):4226-37.

24.

Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines.

Muthumani K, Zhang D, Hwang DS, Kudchodkar S, Dayes NS, Desai BM, Malik AS, Yang JS, Chattergoon MA, Maguire HC Jr, Weiner DB.

Oncogene. 2002 Jul 11;21(30):4613-25.

25.

Plasmid immunization primes unique DTH responses to HIV-1MN envelope epitopes as compared to recombinant protein vaccination.

Chattergoon MA, Maguire HH Jr, Robinson TM, Serrano E, Boyer JD, Weiner DB.

Hybrid Hybridomics. 2002 Apr;21(2):117-22.

PMID:
12031101
26.

Plasmid DNA: is there a Toll on the way to apoptosis?

Chattergoon M, Weiner D.

J Gene Med. 2002 Jan-Feb;4(1):25-6. No abstract available.

PMID:
11828384
27.

Engineering of DNA vaccines using molecular adjuvant plasmids.

Sin JI, Kim J, Chattergoon M, Ayyavoo V, McCallus D, Ugen KE, Boyer JD, Weiner DB.

Dev Biol (Basel). 2000;104:187-98. Review.

PMID:
11713819
28.

Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis.

Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T, Wilson DM, Ayyavoo V, Weiner DB.

Nat Biotechnol. 2000 Sep;18(9):974-9.

PMID:
10973219
29.

Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees.

Bagarazzi ML, Boyer JD, Javadian MA, Chattergoon MA, Shah AR, Cohen AD, Bennett MK, Ciccarelli RB, Ugen KE, Weiner DB.

J Infect Dis. 1999 Oct;180(4):1351-5.

PMID:
10479171
30.

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial.

Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, Nyland S, Lacy KE, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB.

Clin Immunol. 1999 Jan;90(1):100-7.

PMID:
9884357
31.

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.

Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB.

Oncogene. 1998 Dec 17;17(24):3125-35. Erratum in: Oncogene 1999 Apr 8;18(14):2411. Shoemaker H [corrected to Schoemaker H].

32.

HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response.

Boyer JD, Chattergoon M, Shah A, Ginsberg R, MacGregor RR, Weiner DB.

Dev Biol Stand. 1998;95:147-53.

PMID:
9855425
33.

Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees.

Bagarazzi ML, Boyer JD, Ugen KE, Javadian MA, Chattergoon M, Shah A, Bennett M, Ciccarelli R, Carrano R, Coney L, Weiner DB.

Vaccine. 1998 Nov;16(19):1836-41.

PMID:
9795389
34.

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans.

Ugen KE, Nyland SB, Boyer JD, Vidal C, Lera L, Rasheid S, Chattergoon M, Bagarazzi ML, Ciccarelli R, Higgins T, Baine Y, Ginsberg R, Macgregor RR, Weiner DB.

Vaccine. 1998 Nov;16(19):1818-21.

PMID:
9795386
35.

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB.

J Infect Dis. 1998 Jul;178(1):92-100.

PMID:
9652427
36.
37.

Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.

Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB.

Eur J Immunol. 1998 Mar;28(3):1089-103.

38.

Induction of a TH1 type cellular immune response to the human immunodeficiency type 1 virus by in vivo DNA inoculation.

Boyer J, Ugen K, Wang B, Chattergoon M, Tsai A, Merva M, Weiner DB.

Dev Biol Stand. 1998;92:169-74.

PMID:
9554272
39.

Monoclonal antibodies define a cellular antigen involved in HTLV-I infection.

Agadjanyan MG, Chattergoon MA, Petrushina I, Bennett M, Kim J, Ugen KE, Kieber-Emmons T, Weiner DB.

Hybridoma. 1998 Feb;17(1):9-19.

PMID:
9523233
40.

DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees.

Boyer JD, Ugen KE, Chattergoon M, Wang B, Shah A, Agadjanyan M, Bagarazzi ML, Javadian A, Carrano R, Coney L, Williams WV, Weiner DB.

J Infect Dis. 1997 Dec;176(6):1501-9.

PMID:
9395361
41.

Genetic immunization: a new era in vaccines and immune therapeutics.

Chattergoon M, Boyer J, Weiner DB.

FASEB J. 1997 Aug;11(10):753-63. Review.

PMID:
9271360
42.

Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes.

Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R, Chattergoon MA, Dang K, Mahalingam S, Chalian AA, Agadjanyan MG, Boyer JD, Wang B, Weiner DB.

Nat Biotechnol. 1997 Jul;15(7):641-6.

PMID:
9219266
43.

Development of a multicomponent candidate vaccine for HIV-1.

Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon M, Boyer JD, Wang B, Weiner DB.

Vaccine. 1997 Jun;15(8):879-83.

PMID:
9234538
44.

Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB.

Nat Med. 1997 May;3(5):526-32.

PMID:
9142121
45.

Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees.

Bagarazzi ML, Boyer JD, Javadian MA, Chattergoon M, Dang K, Kim G, Shah J, Wang B, Weiner DB.

J Med Primatol. 1997 Feb-Apr;26(1-2):27-33.

PMID:
9271186
46.

In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen.

Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB.

J Immunol. 1997 Jan 15;158(2):816-26.

PMID:
8992999

Supplemental Content

Loading ...
Support Center